LIXTE Biotechnology Holdings (NASDAQ: LIXT) has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
The filing underscores a transformational period for the clinical-stage pharmaceutical and med-tech company. LB-100, a first-in-class clinical PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., the company is also pioneering the development of electronically controlled proton therapy systems for treating tumors. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
The company raised more than $11 million during the year to strengthen its balance sheet and support ongoing operations. For more details on the annual report, the full press release is available at https://ibn.fm/LP6QH.
Additional information about LIXTE can be found at www.lixte.com. Forward-looking statements in the release are subject to risks and uncertainties, including those set forth in the company's SEC filings.
